LadRx Corporation

517 articles about LadRx Corporation

• LadRx Completes Non-Dilutive Financing Transaction for up to $11 Million with XOMA Corporation

  6/22/2023

  XOMA acquires future milestone economics and royalties associated with arimoclomol and aldoxorubicin, allowing LadRx to focus on core LADR assets.

• LadRx Announces Reverse Stock Split Effective as of May 17, 2023

  5/18/2023

  LadRx Corporation today announced that its previously announced reverse stock split of its common stock at a ratio of 1 post-split share for every 100 pre-split shares became effective at 5:00 a.m. PDT on Wednesday, May 17, 2023.

• LadRx Announces Reverse Stock Split

  5/10/2023

  LadRx Corporation today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 100 pre-split shares.

• LadRx Highlights Patent Issued for Its LADR Technology

  3/27/2023

  LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today highlighted that it has been issued a patent from the U.S. Patent and Trademark Office (USPTO) covering the maytansinoid-based drug delivery systems.

• LadRx Announces Review of Strategic Alternatives and Provides Corporate Updates

  3/15/2023

  LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announced today that it has initiated a process to explore a range of strategic and financing alternatives, and provided updates.

• LadRx Corporation Issues Corporate Update for 3Q22

  11/17/2022

  LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today issued the below update to stockholders.

• LadRx Corporation Announces OTCQB Ticker Change to LADX

  10/5/2022

  LadRx Corporation announced it is changing its OTCQB ticker symbol from CYTR to LADX effective Thursday, October 6, 2022.

• CytRx Corporation Relaunches as LadRx Corporation

  9/23/2022

  CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announces that it is relaunching as LadRx Corporation.

• European Patent Office Awards CytRx Key Patent

  9/7/2022

  CytRx Corporation, a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announced it has been awarded a key patent by the European Patent Office, and that the period for parties to oppose the patent has lapsed without opposition.

• CytRx Welcomes Cary J. Claiborne to the CytRx Board of Directors

  8/9/2022

  CytRx Corporation welcomes Mr. Cary J. Claiborne to the CytRx Board of Directors (the “Board").

• CytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock

  5/19/2022

  CytRx Corporation announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.01 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 pm Eastern Time on May 20, 2022.

• CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.

  5/17/2022

  CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to highlight the strategic purchase of arimoclomol by KemPharm, Inc. (“KemPharm”).

• CytRx Partners with Oncology Development Expert to Advance LADR Platform

  4/20/2022

  CytRx Corporation announced it has partnered with oncology development expert Gilad Gordon, MD to assist the Company in developing its next-generation LADR drugs toward first-in-human clinical trials.

• CytRx Announces Integration of Wholly Owned Subsidiary Centurion BioPharma and Corporate Governance Updates

  3/9/2022

  CytRx Corporation, a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announced that the Company is absorbing its wholly-owned subsidiary Centurion BioPharma Corporation.

• CytRx Comments on Orphazyme's Update on European Union Regulatory Review of Arimoclomol in Niemann-Pick Disease Type C

  2/24/2022

  CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), today commented on Orphazyme A/S's (NASDAQ: ORPH) ("Orphazyme") announced update on the ongoing review of the Marketing Authorisation Application for its investigational product candidate, arimoclomol, for the treatment of Niemann-Pick disease type C ("NPC") by the Committee for Medicinal Products for Human Use ("CHMP") of the European Medicines Agency ("EMA").

• CytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C

  2/14/2022

  CytRx Corporation today highlighted Orphazyme A/S for the treatment of Niemann-Pick disease type C ("NPC"). CytRx licensed arimoclomol to Orphazyme in exchange for milestone payments and royalties.

• CytRx to Hold Town Hall for Stockholders on Thursday, January 20th

  1/18/2022

  CytRx Corporation, a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, announced that it will hold a town hall for stockholders on Thursday, January 20, 2022 at 4:30 PM Eastern.

• CytRx to Participate in the H.C. Wainwright BioConnect Virtual Conference

  1/7/2022

  CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that John Caloz, the Company’s Chief Financial Officer, is scheduled to present at the H.C. Wainwright BioConnect Virtual Conference.

• 

  4 Companies Ringing in New Year with New CEOs

  1/5/2022

  Several biopharma companies have adjusted their leadership teams to include new chief executive officers who are expected to guide the companies and their programs into the future.

•  CytRx Announces the Appointment of Dr. Stephen Snowdy as Chief Executive Officer

  1/3/2022

  CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development in oncology and neurodegenerative diseases, today announced that it has appointed Dr. Stephen Snowdy to the role of Chief Executive Officer, effective January 10, 2022.